检索结果-南通市图书馆

Occult hepatitis B virus infection among Egyptian blood donors

World Journal of Hepatology 2013年第2期5卷 64-73页

作者： Zeinab N Said Manal H El Sayed iman i salama Enas K Aboel-Magd Magda H Mahmoud Maged El Setouhy Faten Mouftah Manal B Azzab Heidi Goubran Amal Bassili Gamal E Esmat Microbiology and immunology Department Faculty of Medicine(for Girls)AlAzhar University11511 CairoEgypt Pediatric Department Hematology/Oncology DivisionFaculty of MedicineAin Shams University11511 CairoEgypt Community Medicine Department National Research Center12411 GizaEgypt Ain-Shams Maternity and Women's University Hospital 11511 CairoEgypt Community Enviromental and Occupational Medicine DepartmentFaculty of MedicineAin Shams University11511 CairoEgypt National Blood Transfusion Center 11511 CairoEgypt TB Surveillance officer STB/WHO/EMRO.Focal pointTropical Disease Research11511 CairoEgypt Tropical Medicine Department Faculty of Medicine-Cairo University11511 CairoEgypt

AiM:To identify blood donors with occult hepatitis B virus(HBV) infection(OBi) to promote safe blood ***:Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen(HBsAg),hepatitis C antibody(HCV Ab) and human immunodeficiency virus *** were subjected to the detection of alanine aminotransferase(ALT) and aspartate transaminase(AST) and screening for anti-HBV core antibodies(total) by two different techniques;[Monoliza antibodies to hepatitis B core(Anti-HBc) Plus-Bio-Rad] and(ARC-HBc total-ABBOT).Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface(anti-HBs)(ETi-AB-AUK-3,Dia Sorin-italy).Serum anti-HBs titers > 10 iU/L was considered *** HBV DNA by real time polymerase chain reaction(PCR)(QiAGEN-Germany) with 3.8 iU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were > 1000 iU/***,265 recipients were included,34 of whom were followed up for 3-6 *** were investigated for ALT and AST,HBV serological markers:HBsAg(ETi-MAK-4,Dia Sorin-italy),anti-HBc,quantitative detection of anti-HBs and ***:525/3167(16.6%) of blood units were positive for total anti-HBc,64% of those were antiHBs *** by ARCHiTECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples,where 451(90.6%) confirmed *** for anti-HBc was considered confirmed only if two positive results were obtained for each sample,giving an overall prevalence of 451/3167(14.2%) for total *** DNA was quantified by real time PCR in 52/303(17.2%) of anti-HBc positive blood donors(viral load range:5 to 3.5 x 105 iU/mL) with a median of 200 iU/mL(mean:1.8 x 104 ± 5.1 x 104 iU/mL).AntiHBc was the only marker in 68.6% of *** and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity a

关键词： Hepatitis B virus Total anti-HBc Occult hepatitis B virus infection Hepatitis B surface antigen Hepatitis B virus-DNA

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effectiveness of hepatitis B virus vaccination program in Egypt:Multicenter national project

引用

World Journal of Hepatology 2015年第22期7卷 2418-2426页

作者： iman i salama Samia M Sami Zeinab Nabil Ahmed Said Manal H El-Sayed Lobna A El Etreby Thanaa M Rabah Dalia M Elmosalami Amany T Abdel Hamid Somaia i salama Aida M Abdel Mohsen Hanaa M Emam Safaa M Elserougy Amal i Hassanain Naglaa F Abd Alhalim Fatma A Shaaban Samia A Hemeda Nihad A ibrahim Ammal M Metwally Community Medicine Research Department National Research Center Child Health Department National Research Center Micro--biology and immunology Department Faculty of Medicine (for girls)Al-Azhar University Pediatrics Department Faculty of MedicineAin-Shams University Dermatology and Venereology Department National Research Center Environmental and Occupational Medicine Department National Research Center

AiM:To assess the effectiveness of hepatitis B virus(HBV) vaccination program among fully vaccinated ***:A national community based crosssectional study was carried out in 6 governorates representing Egypt. A total of 3600 children aged from 9 mo to 16 years who were fully vaccinated with HBV vaccine during infancy were recruited. Face to face interviews were carried out and sera were evaluated for hepatitis B surface antigen(HBsA g),anti-HBV core antibodies(total) and quantitative detection of hepatitis B surface antibody using enzyme linked immunoassays techniques. Samples positive to HBs Ag/anti-HBV core antibodies were subjected to quantitative HBV-DNA detection by real time polymerase chain reaction with 3.8 iU/L detection limit. RESULTS:Sero-protection was detected among 2059 children(57.2%) with geometric mean titers 75.4 ± 3.6 iU/L compared to 3.1 ± 2.1 iU/L among nonseroprotected children. Multivariate logistic analysis revealed that older age and female gender were the significant predicting variables for having non seroprotective level,with adjusted odds ratio 3.3,9.1and 14.2 among children aged 5 to ively compared to those irls compared to boys with P itive in 0.11% and breakthrough infection was 0.36% and 0.39% depending on positivity of anti-HBc and DNA detection respectively. The prevalence of HBV infection was significantly higher among children aged ≥ 7 years(0.59%) compared to 0.07% among younger children with odds ratio equal to 8.4(95%Ci:1.1-64.2) and P igher among girls(0.48%) than boys(0.29%) with P > 0.05. C ON C LU S i ON :T he E gy pt ian c ompuls or y H B V vaccination program provides adequate protection. Occult HBV infection exists among apparently healthy vaccinated children. Adherence to infection control measures is mandatory.

关键词： Hepatitis B virus immunization Seroprotection Brea

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection

引用

World Journal of Hepatology 2022年第6期14卷 1053-1073页

作者： iman ibrahim salama Hala M Raslan Ghada A Abdel-Latif Somaia i salama Samia M Sami Fatma A Shaaban Aida M Abdelmohsen Walaa A Fouad Department of Community Medicine Research National Research CenterGiza 12622DokkiEgypt Department of internal Medicine National Research CenterGiza 12622DokkiEgypt Department of Child Health National Research CenterGiza 12622DokkiEgypt

Hepatitis C virus(HCV)is a common cause of liver disease and is associated with various extrahepatic manifestations(EHMs).This mini-review outlines the currently available treatments for HCV infection and their prognostic effect on hepatic manifestations and ***-acting antiviral(DAA)regimens are considered pan-genotypic as they achieve a sustained virological response(SVR)>85%after 12 wk through all the major HCV genotypes,with high percentages of SVR even in advanced fibrosis and *** risk factors for DAA failure include old males,cirrhosis,and the presence of resistance-associated substitutions(RAS)in the region targeted by the received *** effectiveness of DAA regimens is reduced in HCV genotype 3 with baseline RAS like A30K,Y93H,and ***,the European Association for the Study of the Liver recommended the identification of baseline RAS for HCV genotype *** higher rate of hepatocellular carcinoma(HCC)after DAA therapy may be related to the fact that DAA regimens are offered to patients with advanced liver fibrosis and cirrhosis,where interferon was contraindicated to those *** change in the growth of pre-existing subclinical,undetectable HCC upon DAA treatment might be also a ***,after DAA therapy,the T cell-dependent immune response is much weaker upon HCV clearance,and the down-regulation of TNF-αor the elevated neutrophil to lymphocyte ratio might increase the risk of *** can result in reactivation of hepatitis B virus(HBV)in HCV coinfected *** are effective in treating HCV-associated mixed cryoglobulinemia,with clinical and immunological responses,and have rapid and high effectiveness in *** improve insulin resistance in 90%of patients,increase glomerular filtration rate,and decrease proteinuria,hematuria and articular *** clearance by DAAs allows a significant improvement in atherosclerosis and metabolic and immunological conditions,with a reduction of m

关键词： Hepatitis C virus Hepatic Extrahepatic Direct-acting antivirals impact

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current and novel modalities for management of chronic hepatitis B infection

引用

World Journal of Hepatology 2023年第5期15卷 585-608页

作者： iman ibrahim salama Samia M Sami Somaia i salama Ghada A Abdel-Latif Fatma A Shaaban Walaa A Fouad Aida M Abdelmohsen Hala M Raslan Department of Community Medicine Research National Research CentreGiza 12411DokkiEgypt Department of Child Health National Research CentreGiza 12411DokkiEgypt Department of internal Medicine National Research CentreGiza 12411DokkiEgypt

Over 296 million people are estimated to have chronic hepatitis B viral infection(CHB),and it poses unique challenges for *** is the result of hepatitis B virus(HBV)-specific immune tolerance and the presence of covalently closed circular DNA as mini chromosome inside the nucleus and the integrated *** hepatitis B core-related antigen is the best surrogate marker for intrahepatic covalently closed circular *** HBV“cure”is the durable loss of hepatitis B surface antigen(HBsAg),with or without HBsAg seroconversion and undetectable serum HBV DNA after completing a course of *** currently approved therapies are nucleos(t)ide analogues,interferon-alpha,and *** these therapies,functional cure can be achieved iniation to HBV or the host immune system that disrupts the interaction between them can lead to reactivation of *** therapies may allow efficient control of *** include direct acting antivirals and *** of the viral antigen load is a crucial factor for success of immune-based *** therapy may lead to modulation of the host immune *** may enhance/restore innate immunity against HBV(as toll-like-receptors and cytosolic retinoic acid inducible geneⅠagonist).Others may induce adaptive immunity as checkpoint inhibitors,therapeutic HBV vaccines including protein(HBsAg/pre S and hepatitis B core antigen),monoclonal or bispecific antibodies and genetically engineered T cells to generate chimeric antigen receptor-T or T-cell receptor-T cells and HBV-specific T cells to restore T cell function to efficiently clear *** therapy may successfully overcome immune tolerance and lead to HBV control and *** approaches carry the risk of overshooting immune responses causing uncontrolled liver *** safety of any new curative therapies should be measured in relation to the excellent safety of currently appro

关键词： immunity infection overcome

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：